Impact of tRNA modifications and tRNA-modifying enzymes on proteostasis and human disease by Pereira, Marisa et al.
 International Journal of 
Molecular Sciences
Review
Impact of tRNA Modifications and tRNA-Modifying
Enzymes on Proteostasis and Human Disease
Marisa Pereira, Stephany Francisco, Ana Sofia Varanda, Mafalda Santos , Manuel A. S. Santos
and Ana Raquel Soares *
Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro, 3810 Aveiro, Portugal;
marisa.pereira@ua.pt (M.P.); s.marquesfrancisco@ua.pt (S.F.); sofiavaranda@ua.pt (A.S.V.);
santos.mafalda@ua.pt (M.S.); msantos@ua.pt (M.A.S.S.)
* Correspondence: ana.r.soares@ua.pt; Tel.: +3-512-3424-7229
Received: 31 October 2018; Accepted: 20 November 2018; Published: 24 November 2018 
Abstract: Transfer RNAs (tRNAs) are key players of protein synthesis, as they decode the genetic
information organized in mRNA codons, translating them into the code of 20 amino acids.
To be fully active, tRNAs undergo extensive post-transcriptional modifications, catalyzed by different
tRNA-modifying enzymes. Lack of these modifications increases the level of missense errors and
affects codon decoding rate, contributing to protein aggregation with deleterious consequences to the
cell. Recent works show that tRNA hypomodification and tRNA-modifying-enzyme deregulation
occur in several diseases where proteostasis is affected, namely, neurodegenerative and metabolic
diseases. In this review, we discuss the recent findings that correlate aberrant tRNA modification
with proteostasis imbalances, in particular in neurological and metabolic disorders, and highlight the
association between tRNAs, their modifying enzymes, translational decoding, and disease onset.
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1. Introduction
Transfer RNAs (tRNAs) are the main players of translation machinery, carrying the amino acids
required for nascent peptides being formed at the ribosome [1]. In humans, there are 610 genes that
code for cytosolic and mitochondrial tRNAs (mt-tRNAs). These adaptor molecules recognize mRNA
codons through their anticodons and decode the 20 standard amino acids of the cellular proteome,
linking the genetic code information to amino acid identity [2]. Codon–anticodon recognition between
the first and second bases of codons and the third and second bases of anticodons is determined by
Watson–Crick pairing rules (A:U; U:A; G:C; C:G). On the other hand, the interaction between the
third base of codons and the first base of anticodons (position 34 of the tRNA, also known as the
wobble position) is more flexible, as it allows non-Watson–Crick base pairing (wobble hypothesis) [1,3].
This means that multiple codons can code for a single amino acid and a given tRNA may read more
than one synonymous codon.
To ensure tRNA stability, translational efficiency, and fidelity, tRNAs are extensively modified
post-transcriptionally like other RNA molecules, such as rRNA and mRNA [4]. To date, more than
80 tRNA modifications have been reported and an average of 13 modified bases can be found per tRNA
molecule [5,6]. All of these modifications are catalyzed by different classes of tRNA-modifying enzymes
and both cytosolic and mt-tRNAs are modified. Although several modifications are shared by both
tRNA types, as is the case of N6-isopentenyl modification to adenosine (i6A) modification at position
37 of tRNAs [7], specific modifications are unique to a tRNA type, as is the case of taurine-derived
modifications that are exclusively of mt-tRNAs [8].
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Modifications occurring at or near the anticodon loop, in particular at positions 34 and 37,
are highly conserved in eukaryotes and affect specific codon–anticodon interactions, regulating
translational efficiency and fidelity. In fact, the vast majority of tRNA modifications occur at
the wobble position (position 34), ensuring the correct codon–anticodon base pairing and reading
frame maintenance while preventing translational frameshifting [9]. Modifications at this position
are generally associated with decoding by increasing the diversity of codon recognition through
codon–anticodon wobbling. Post-transcriptional modifications at base 37, adjacent to the anticodon
loop, help to stabilize codon–anticodon interactions by improving intrastrand stacking interactions
between codon and anticodon bases and within the anticodon loop [10].
Modifications occurring within the structural core of tRNAs, namely, in the D- or T- loops, are
required for tRNA stability and functional folding [11], and their absence can lead to tRNA degradation
and tRNA pool imbalances (Figure 1). The pseudouridine modifications, for example, stabilize specific
structural motifs, and dihydrouridines help to maintain conformational flexibility (reviewed in [12]).
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O-methylcytidine; m3C, 3-methylcytidine Gm, 2′-O-methylguanosine; ncm5Um, 5-carbamoylmethyl-2′-O-
methyluridine; m5C, 5-methylcytosine; ncm5mU, 5-methoxycarbonylmethyluridine; mcm5s2U, 5-
methoxycarbonylmethyl-2-thiouridine; Q, queuosine; s2U, 2-thiouridine τm5U, 5-taurinomethyluridine; 
τm5s2U, 5-taurinomethyl-2-thiouridine; I6A, N6-isopentenyladenosine; ms2t6A, 2-methylthio-N6-threonyl 
carbamoyladenosine; Ψ, pseudouridine; m1A, 1-methyladenosine. 
As previously mentioned, the wobble position is often modified in various tRNAs (Figure 1). In 
eukaryotes, 11 cytoplasmic tRNAs carry 5-methoxycarbonylmethyl (mcm5) or 5-carbamoymethyl 
(ncm5) modifications at Uridine 34 (U34). These modifications are catalyzed by the Elongator 
complex, a protein complex composed of six proteins, namely, ELP1 (or IKBKAP), ELP2, ELP3, ELP4, 
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ms2t6A, 2-methylthio-N6-threonyl carbamoyladenosine; Ψ, pseudouridine; m1A, 1-methyladenosine.
As previously mentioned, the wobble position is often modified in various tRNAs (Figure 1).
In eukaryotes, 11 cytoplasmic tRNAs carry 5-methoxycarbonylmethyl (mcm5) or 5-carbamoymethyl
(ncm5) modifications at Uridine 34 (U34). These modifications are catalyzed by the Elongator complex,
a protein complex composed of six proteins, namely, ELP1 (or IKBKAP), ELP2, ELP3, ELP4, ELP5,
and ELP6 [13]. ALKBH8 and its yeast homolog Trm9 are other methyltransferases required for the
final step of mcm5 biogenesis at the wobble position [14,15]. Following mcm5U34 modification of
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tRNALys(UUU), tRNAGln(UUG), and tRNAGlu(UUC), a 2-thio group is added by ubiquitin-ligase-like
proteins, namely, Urm1, Uba4, Ncs2, and Ncs6, resulting in 5-methoxycarbonylmethyl-2-thiouridine
(mcm5s2) [16] (Figure 1). These modifications have been consistently correlated with translational
fidelity and proteostasis [14,16–21].
U34 of a subset of mt-tRNAs contains taurine-derived modifications that are required for
mitochondrial translation through codon–anticodon stabilization. Lack of this modification has been
associated with MELAS and MERRF (myoclonus epilepsy with ragged red fibers), as fibroblast
cells derived from MELAS and MERRF patients carrying A3243G mutations in mt-tRNALeu(UUR)
and A8344G mutations in mt-tRNALys, respectively, lack the characteristic τm5U and τm5s2U
modifications [22]. U34 of the human mt-tRNALys, mt-tRNAGlu, and mt-tRNAGln carry a m5s2
modification catalyzed by TRMU [23]. A particular mutation in this enzyme, namely, A10S, has been
correlated with the phenotypic manifestations of deafness and results in mt-tRNA hypomodification,
impairment of mitochondrial translation, and an increased level of reactive oxygen species [23,24].
Other nucleotides at and near the anticodon are also subjected to modifications (Figure 1).
The Cytosine 34 (C34) and Cytosine 48 (C48) of tRNALeu(CAA) are methylated to 5-methylcytosine
(m5C) by NSUN2 and the absence of these modifications leads to the accumulation of
tRNA-derived fragments [25,26]. Guanosine 34 (G34) and cytidine 32 (C32) are methylated by the
2′-O-ribose-methyltransferase FTSJ1 in tRNAPhe and lack of these modifications has been consistently
correlated to X-linked mental retardation [27,28]. G34 in tRNAs with GUN anticodons, namely,
tRNAAsp, tRNAHis, and tRNATyr, is exchanged by queusine (Q) by the tRNA-ribosyltransferase
(TGT) [29] (Figure 1). This modification is dependent on the availability of the substrate Q that in
eukaryotes can only be retrieved by diet, as it is only synthesized de novo by bacteria. Recent studies
have linked Q availability and modification to translation fidelity and genome recoding [30].
Adenosine (A) to inosine (I) (A-to-I) editing also occurs in tRNAs. The I modification is found
at the wobble position as well as at positions 37 and 57. This modification is catalyzed by adenosine
deaminases (ADATs) and expands the tRNA decoding capacity in ANN tRNAs as inosine-modified
tRNAs can pair with U-, C-, and A-ended codons [31] (Figure 1). However, it is worth noting that
I37 and I57 are further methylated to m1I37 or m1I57 and that m1I37 is only found in the eukaryotic
tRNAAla [32].
N6-threonylcarbamoyladenosine (t6A) and i6A are conserved modifications found at A37 of
several tRNAs. As other modifications at position 37, they are important to maintain the reading frame
during decoding, promoting translation efficiency. t6A37 modifications occur in 5 mt-tRNAs, namely,
tRNASer, tRNAThr, tRNAAsn, tRNAIle, and tRNALys, and low levels of this modification have been
recently associated with MERFF [33], neurodegeneration [34], and diabetes [35]. i6A37 modification
increases translation fidelity and efficiency of cognate codons, and i6A37 hypomodification is
associated with mitochondrial defects in different organisms [7,36].
Methylation at G37 of tRNAPhe is necessary for the formation of wybutosine (yW), which is
crucial for the maintenance of the reading frame, preventing ribosome slippage on the phenylalanine
UUU and UUC codons [10] (Figure 1). Uridines are often modified to pseudouridines at positions 38
and 39, broadening the decoding capacity of tRNAs (Figure 1). For example, modified tRNALeu(CAA)
can decode stop UAG codons leading to stop-codon readthrough. In the absence of pseudouridine
modification, the decoding ability of the tRNA is altered and it is not able to recognize the stop
codon [37].
tRNA modifications have been extensively characterized in Saccharomyces cerevisiae and
different studies correlate tRNA hypomodification with decreased translation accuracy and
proteome imbalances in yeast [14,16–18]. Recent developments in next-generation sequencing [38],
mass spectrometry [39], and ribosome profiling [40] have enabled the assessment and quantification of
tRNA modifications and amino acid misincorporation [41,42], as well as its correlation with translation
efficiency. This has contributed to significant advances in the field in the last years. In fact,
the relevance of tRNA modifications in higher eukaryotes is starting to emerge, as deregulation of both
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tRNA modifications and tRNA-modifying enzymes has been found in several diseases, namely,
neurological diseases, cancer, and mitochondrial-linked disorders. In this review, we focus on
the recent findings that correlate aberrant cytosolic and mitochondrial tRNA modifications with
proteostasis imbalances, with a particular focus on human conformational disorders. We highlight
the association between tRNAs, their modifying enzymes and translation fidelity, and explore their
therapeutic potential.
2. Proteome Disruption in Yeast upon U34 Hypomodification
A growing number of reports show that tRNA hypomodification, in particular at the wobble
position (position 34) or adjacent to the anticodon (e.g., position 37), affects translational accuracy and
fidelity, leading to the accumulation of misfolded and aggregated proteins as well as activation of
the cellular stress response. This is due to the fact that modifications at or near the anticodon
have a direct impact in codon–anticodon interactions, ensuring base pairing flexibility and reading
frame maintenance.
U34 mcm5 and ncm5 modifications are catalyzed by the Elongator complex [13], which is
also engaged in transcriptional elongation and histone acetylation [43]. In yeast, this complex
catalyzes the formation of cm5U34 that is then used as a substrate by the methyltransferase
Trm9 for the formation of mcm5U34 of tRNALys(UUU), tRNAGln(UUG), tRNAGly(UCC), tRNAArg(UCU),
and tRNAGlu(UUC). Three of these tRNAs, namely, tRNALys(UUU), tRNAGln(UUG) and tRNAGlu(UUC),
are further modified at the wobble position with a 2-thio group, resulting in mcm5s2 nucleotide,
catalyzed by Urm1 and other ubiquitin-ligase-like proteins, namely, Uba4, Ncs2 and Ncs6 [9,14,16]
(Figure 2). Disruption of these modifications leads to proteome instability in yeast. For example,
Trm9 yeast mutants are deficient in 2 of 23 tRNA modifications, namely, mcm5U and mcm5s2U,
as determined by LC-MS. The absence of these modifications in Trm9 mutants leads to amino
acid misincorporations and frameshifting errors during the translation of specific codons, namely,
those belonging to arginine, glutamic acid, glutamine, and lysine mixed codon boxes, linking these
wobble base modifications to translational fidelity [44]. Increase in translational errors in Trm9 mutants
is accompanied by activation of the unfolded protein response (UPR) and activation of the heat shock
response, key protein quality control mechanisms that are activated to refold or clear unfolded proteins,
preventing the accumulation of toxic protein aggregates in cells [44]. Moreover, translation of AGA
and GAA codons is enhanced in the presence of the modifications catalyzed by Trm9 as well as the
translation elongation speed through these codons relative to Trm9 yeast mutants [45]. The absence of
Trm9 results in hypomodification of tRNAArg(UCU) and tRNAGlu(UUC) and is directly correlated with
a decrease in the synthesis of proteins enriched in AGA and GAA codons, mainly due to ribosome
stalling during translation. The vast majority of these proteins are involved in protein synthesis,
cell cycle control, and DNA damage response and are consistently downregulated either under normal
or stress conditions in Trm9 mutants, showing that lack of modifications impairs the cell’s ability to
respond to stress [14]. Taken together, these results suggest that tRNA modifications are important for
the regulation of codon-biased translation.
Similarly, yeast cells lacking Elp3, one of the components of the Elongator complex, and Urm1,
which together are required to generate the mcm5s2U modification at U34 of tRNALys, tRNAGlu,
and tRNAGln, have lower resistance to stress due to inefficient translation of stress-related genes
enriched for AAA, CAA, and GAA codons [16,46]. Interestingly, overexpression of tRNALys(UUU) is
sufficient to reverse the stress defects of Schizosaccharomyces Pombe Elp3 mutant [46]. Another double
yeast mutant for Elp3 and Uba4 that also lacks mcm5s2U displays impaired protein synthesis that is
partially restored by overexpression of hypomodified tRNALys(UUU) [47].
Also, overexpression of hypomodified tRNALys(UUU), tRNAGlu(UUC), and tRNAGln(UUG) restore
CAA and AAA codon translation rates and protein homeostasis in Ncs2 and Elp6 yeast mutants
that lack 2-thiolation and mcm5/ncm5 modifications, respectively [18]. Ribosome profiling of these
mutants revealed increased ribosome occupancy at CAA and AAA codons, indicative of a translational
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slowdown. Moreover, proteotoxic stress is triggered in these yeast mutants, probably as a response
to the accumulation of protein aggregates upon aberrant U34 modification. Metastable proteins
are the class of proteins with the highest tendency for aggregation upon loss of U34 modifications,
and Ncs2Elp6 double mutants have impaired ability to restore proteostasis [18]. However, contrary to
the study by Deng et al. [14], Ncs2Elp6 double yeast mutants lacking U34 mcm5s2 modifications
do not display an impaired translation of stress response genes enriched in codons affected by U34
hypomodification but rather a chronic protein misfolding that causes a reduced ability for cells to
restore proteostasis [18]. Since both studies used different yeast strains and mutants, it is possible that
these divergent results may translate differences in genetic backgrounds.
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catalyzed by the Elongator complex (Elp1–Elp6), Trm9, and Urm1 enzymes and the ubiquitin-ligase-like
proteins, namely, Uba4, Ncs2, and Ncs6. In yeast, the Elongator complex (Elp1–Elp6) catalyze
the wobble uridine (U34) modifications that form 5-carbamoylmethyluridine (ncm5U34) and
5-carboxymethyluri ine (cm5U34). Then, the methyltransferase Trm9 uses cm5U34 as a substrate
in different tRNAs: RNA Lys(UUU) tRNA Gln(UUG), tRNA Gly(UCC), tRNA Arg(UCU), and tRNA Glu(U C).
Subsequent addition of a 2-thiol group by an enzyme cascade involving Urm1 a d Uba4, Ncs2, and Ncs6
occurs in three of these tRNAs: (tRNALys(UUU), tRNAGln(UUG), and tRNAGlu(UUC)). All modified
nucleosides prese ted in this figure can be found in the MODOMICS datab se. Red dashed
boxes represent the modification catalyzed by the respective enzymes in each step. Abbreviations:
tRNA, transfer RNA; ncm5U, 5-carbamoylmethyluridine; cm5U, 5-carboxymethyluridine; cm5U,
5-methoxycarbonylmethyluridine; mcm5s2U, 5-methoxycarbonylmethyl-2-thiouridine.
Accumulation of protein aggregates is also observed in budding yeast lacking U34 mcm5s2 and
pseudouridine (ψ) at positions 38 in tRNAGln(UUG) [17]. These mutants also display an impaired
synthesis of the Gln-rich prion Rnq1. Similar to other studies [18,46], translational defects are rescued
upon tRNAGln(UUG) overexpression, indicating that both mcm5s2U and ψ38 are key for this tRNA
decoding [17].
Taken together, these studies demonstrate that deregulation of tRNA modifications mainly affects
protein synthesis rate. In fact, absence of wobble modifications leads to ribosome stalling in particular
codons and expression deregulation of protein subsets enriched in those codons. Altered levels of
these proteins may trigger the cellular stress response or affect the cell′s ability to respond to stress
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conditions. Besides aberrant protein synthesis, tRNA hypomodification, in particular of U34, is directly
correlated with accumulation of protein aggregates and proteostasis imbalances that may result from
ribosome stalling and subsequent protein folding defects. As overexpression of hypomodified tRNAs
restores both translation rates and proteostasis, further studies are needed to elucidate what is the
underlying cause of the accumulation of misfolded proteins.
Since most of these tRNA modifications, as well as the respective tRNA-modifying enzymes, are
conserved among eukaryotes, it is reasonable to speculate that similar phenotypes can occur in higher
eukaryotes and that tRNA hypomodification can be an underlying cause of several human diseases
where proteostasis is affected. One of the first studies recapitulating similar phenotypes in higher
eukaryotes was performed in Caenorhabditis elegans. A U34 2-thiolation-deficient C. elegans strain
displayed ribosome stalling at AAA, CAA, and GAA codons, similar to the yeast Ncs2 mutant [18].
These mutant animals also had a 2.5-fold higher protein aggregate burden when compared to
the controls as well as an increase in the expression of heat shock proteins, indicating that tRNA
hypomodification at U34 disrupts proteostasis in nematodes [18].
Proteostasis imbalances together with deregulation of the UPR are often observed in Alzheimer′s,
Parkinson′s, or amyotrophic lateral sclerosis (ALS), as well as in type 2 diabetes and cancer [48–50].
Several tRNA-modifying enzymes were previously found to be deregulated or mutated in most of
these disorders, but only recently have researchers started focusing on the correlation between
tRNA modifications and the translation imbalances observed in these disorders. In the next section,
the recent advances establishing a link between human diseases and tRNA modification deregulation
are discussed.
3. Deregulation of tRNA Modifications in Protein Conformational Diseases
The first report of a tRNA mutation linked to disease was a point mutation in the
mitochondrial tRNALeu(UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis,
and stroke-like episodes) discovered in 1990 [51]. Since then, several tRNA mutations, as well as
deregulation and/or mutation of tRNA-modifying enzymes, have been reported in a panoply of
human diseases ranging from neurological disorders to metabolic imbalances and cancer [52].
From the analysis of the existing literature, it is possible to infer that while tRNA modifications
are generally negatively affected in metabolic and neurodegenerative diseases [20,27,53–56],
hypermodified tRNAs and upregulation of tRNA-modifying enzymes are often found in different
cancers [57,58]. It is worth noting that the same tRNA-modifying enzyme can be affected differently in
unrelated diseases, ultimately affecting the levels of tRNA modifications catalyzed by it. For example,
mutations in NSUN2, a tRNA-modifying enzyme that methylates cysteine to m5C, are associated with
neurological defects and tRNA hypomodification [59,60], while upregulation of this enzyme has been
found in different tumors and has been associated with poor prognosis of head and cancer squamous
carcinoma [61,62].
It is possible that these observations are correlated with the different types of proteome imbalances
observed in these disorders. While neurodegenerative disorders are characterized by the generation of
unfolded proteins that accumulate as protein aggregates [48,63], protein synthesis rate is generally
upregulated in cancer. Indeed, tumors are characterized by increased cellular proliferation and
increased protein synthesis rate, but not all tRNAs are equally upregulated in cancer, raising the
possibility that cancer cells have distinct tRNA pools that may more efficiently translate subsets of
oncogenes [57,58]. For example, upregulation of the initiator tRNAMet [64] as well as upregulation of
tRNA-modifying enzymes [61,65] contribute to cancer initiation and progression.
3.1. Role of Elongator Complex, mcm5, ncm5, and mcm5s2 Modifications in Neurological Disorders
Mutations in the donor splice site of intron 20 of ELP1/IKBKAP gene (an Elongator complex
subunit) have been linked to familial dysautonomia (FD) (Figure 3; Table 1), a hereditary genetic
disorder characterized by improper development and function of the sensorial and autonomic nerve
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systems [66]. In fact, most cases of FD (99.5%) result from a single nucleotide point mutation in the
IKBKAP gene [67], and brain tissue as well as fibroblast cell lines from FD patients have reduced
levels of mcm5s2U modification [68]. Hypomodification of the wobble uridine of tRNAs for Val,
Gly, Thr, and Arg of FD patient cells was reverted after rectifying the aberrant splicing of IKBKAP
pre-mRNAs harboring an FD-causing mutation [69]. Recovery of tRNA modification levels led to
the concomitant recovery of cell growth [69]. Consistently, elp1 C. elegans mutants that lack mcm5s2U
nucleosides display impaired protein synthesis and deficient chemosensory neurons [70]. Moreover,
knockout of Ikbkap results in embryonic lethality in mice, while mice central nervous system conditional
knockouts of this protein are characterized by developmental neurological defects [71]. Also, Ikbkap
conditional knockouts in mice testes display defects in meiotic progression and significantly reduced
levels of mcm5U, ncm5U, and mcm5s2U [72]. Conditional Ikbkap/Elp1 knockout mice recapitulate
FD hallmarks and also display reduced levels of mcm5s2U nucleosides [19]. Moreover, translation of
large, AA-biased genes involved in DNA damage repair, such as Brca2, was negatively affected in
these knockouts, resulting in increased DNA damage and UPR activation [19], similar to what was
previously observed in yeast [18]. Taken together, these results establish an association between
Elongator complex dysfunction, defects in tRNA modification, inefficient translation, UPR, and FD
onset and progression.
ELP3 has also been associated with neurological defects (Figure 3; Table 1). Allelic variants of
the ELP3 gene have been associated with sporadic ALS, a neurodegenerative disease characterized by
degeneration of motor neurons [53]. Mutations in SOD1, FUS, C9orf72, and TDP-43 are also related to
ALS onset, and wildtype ELP3 expression is associated with increased survival of patients carrying
a C9orf72 repeat expansion [73]. This tRNA-modifying enzyme is also required for proper neuronal
function and survival, as drosophila and zebrafish embryos lacking ELP3 develop motor axonal
abnormalities that recapitulate the phenotypes induced by mutant SOD1 and TDP-43 [53]. Moreover,
axonopathy was attenuated after ELP3 coexpression in two ALS zebrafish models, namely, SOD1 and
C9Orf72 mutants, reinforcing the protective role of ELP3 in ALS [20]. On the other hand, deletion of
ELP3 in mice is lethal and constitutive heterozygous deletion of ELP3 accelerates disease onset and
leads to a decrease of mcm5s2U nucleosides in tRNAs [20]. Ribosome profiling of the forebrains of
another ELP3 conditional knockout mouse model confirmed ribosome stalling of codons read by
ncm5/mcm5-modified tRNAs and UPR activation [74]. Similarly, ELP3 C. elegans mutants lack ncm5U
and mcm5s2U tRNA modifications and exhibit neurological and developmental defects as well as
reduced translation [70]. Moreover, silencing of ELP3 in NSC34 cells leads to a 28% increase in total
protein aggregation and increases the level of insoluble mutant human SOD1. ELP3 overexpression
reduces the amount of insoluble SOD and restores the levels of mcm5s2U in approximately 50%,
correlating this modification with SOD1 solubility [20]. Importantly, the reduced levels of ELP3 are
directly correlated with the levels of mcm5s2U in motor cortices of ALS sporadic patients, suggesting
that ELP3 is a modifier of the disease by affecting protein aggregation of particular proteins through
the control of the wobble modification [20,74].
Mutations in other Elongator complex subunits, namely, ELP2 and ELP4, have been correlated
with neurodevelopmental disabilities and rolandic epilepsy, respectively (Figure 3; Table 1). ELP2
mutations were identified by next-generation sequencing in intellectual disability patients [54,75]. ELP2
Single-nucleotide polymorphisms (SNPs) were also identified by genome-wide association studies
(GWAS) in patients with frontotemporal dementia [76]. The association of ELP4 with rolandic epilepsy
is contradictory, as there are studies identifying this gene as a risk locus for the disease [77] and studies
demonstrating that there is no association of ELP4 SNPs with centrotemporal spikes [78]. However,
to date, there are no studies correlating ELP2 or ELP4 mutations with translational alterations and
deregulated levels of tRNA wobble modifications in these disorders, but given the consequences of
ELP1 and ELP3 deregulation in other neurological disorders and that neurons are extremely sensitive to
increased translational error rate [37], it is expected that tRNA hypomodification and translation
slow-down also occur in the absence of other Elongator complex components.
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Table 1. List of tRNA ModEnz, tRNA modifications, and tRNA deregulations associated with neurological and metabolic disorders.
tRNA ModEnz tRNA Modifications Neurological and Metabolic Disorders tRNAs Deregulated References
IKBKAP (ELP1)
mcm5U34, mcm5s2U34,
ncm5U34, ncm5Um34
Familial dysautonomia (FD) tRNA
Gln (UUG)
tRNALys (UUU)
[19,66–69]
ELP2 Neurodevelopmental disabilities Several [54,75,76]
ELP3 Amyotrophic lateral sclerosis (ALS)
tRNAGln (UUG)
tRNALys (UUU)
tRNAGlu (UUC)
[20,53]
ELP4 Rolandic epilepsy Several [77,78]
FTSJ1 mC32, mC34, mG34, ncm5mU34 Nonsyndromic X-linked intellectual disability
tRNALeu
tRNAPhe
tRNATrp
[27,28,79]
TRMT1 m2,2G26 Autosomal-recessive intellectual disability; Several [56,80]
NSUN2 m5C34, m5C48, m5C49, m5C50 Autosomal-recessive intellectual disability; Dubowitz-like syndrome
tRNALeu (CAA)
tRNAGly (GCC)
[55,59,60]
TRMT10A (RG9MTD2) m1G9 Microcephaly, epilepsy, intellectual disability, type 2 diabetes Several [81–85]
PUS3 ψU38, ψU39 Autosomal-recessive intellectual disability tRNAPhe [86]
ADAT3 A-to-I editing Intellectual disability
tRNAAla, Pro, Thr
tRNAVal, Ser, Arg
tRNALeu, Ile
[87,88]
CDKAL1 ms2t6A37 Type 2 diabetes tRNALys (UUU) [35,89,90]
TRMT61B m1A58
Alzheimer´s disease
MERRF
mt-tRNALeu (UUR)
mt-tRNALys (UCN)
mt-tRNASer
[91,92]
MTO1 τm5U34 MELAS mt-tRNALeu(UUR) [8,21,22]
GTPBP3 τm5s2U34 MERRF Mt-tRNALys [8,22]
TRIT1 I6A37 Mitochondrial disorders Mt-tRNASer(UCN) [7]
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3.2. Impact of Other Anticodon Modifications in Neurological and Metabolic Diseases
Besides uridylations and thiolations, the wobble position of tRNAs is subjected to other
modifications such as m5C, Gm34, and A-to-I editing catalyzed by NSUN2, FTSJ1, and ADAT3,
respectively. FTSJ1 also catalyzes Cm32 modifications and NSUN2 also methylates C47 and C48.
FTSJ1 mutations are linked to nonsyndromic X-linked intellectual disability (Figure 3; Table 1),
a genetically and clinically heterogeneous group of brain disorders [27,28,79]. Patient cell lines bearing
disease-causing FTSJ1 mutations display 2′-O-methylation hypomodification at the anticodon loop of
tRNAPhe, providing evidence that FTSJ1 also catalyzes this modification in humans and that lack of
Gm34 may be a trigger for X-linked intellectual disability [27].
Different studies implicate mutations in NSUN2 in autosomal-recessive intellectual disability
(Figure 3; Table 1), and drosophila mutants lacking the NSUN2 ortholog have severe short-term
memory deficits, linking NSUN2 and RNA methylation to cognitive development [55,59]. A splicing
mutation in NSUN2 is also present in Dubowitz-like syndrome patients that are characterized by
microcephaly, mental retardation, and peculiar faces. This mutation is sufficient for reduction of
both NSUN2 mRNA and protein levels in cultured fibroblast from patients and results in the loss of
m5C modifications on C47 and C48 of the tRNAAsp(GTC), a NSUN2 substrate [60]. NSUN2 mutant
mice show reduced m5C at C34 of NSUN2 substrate tRN Leu(CAA) [93]. Moreover, mice lacking
two methyltransferases, namely, NSUN2 and DNMT2, are also characterized by m5C loss in tRNAs
followed by tRNA degradation, developmental defects, and lethality. These double mutants are also
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characterized by decreased protein synthesis rate [94], which is also observed in NSUN-2-deficient
mouse brains [26], correlating once again tRNA modifications with protein synthesis regulation.
DNMT2 (TRDMT1) polymorphisms have been also associated with spina bifida risk and increased
folate levels in red blood cells [95].
A single missense mutation identified in ADAT3 by exome sequencing can cause severe
intellectual disability and strabismus [87,88,96], implicating another gene involved in protein
translation in the development of neurological diseases (Figure 3; Table 1). Recently, a second
mutation in ADAT3 was reported in a patient with mild intellectual disability [97]. Although the
levels of A-to-I editing in the patients carrying these mutations were not analyzed, the resulting
phenotypes are similar to the ones obtained when other tRNA-modifying enzymes that catalyze
wobble modifications are mutated. This reinforces the fact that wobble modifications, independently of
which type, are crucial to translation efficiency and disturbance of these modifications affect the
translation of essential genes for brain development.
Deficiency in MTO1, the enzyme that catalyzes taurine modifications, leads to complete loss of this
modification in mt-tRNAs in both cell lines and mice, as well as impaired mitochondrial translation,
accumulation of misfolded mitochondrial proteins, and UPR activation [21]. Human fibroblasts
carrying a homozygous mutation in the MTO1 also display hypomodification of mt-tRNAs and
upregulation of proteostasis stress-related genes [98]. Treatment of MTO1-deficient cells with the
chemical chaperone TUDC, that has been tested successfully in ALS patients [99], alleviated the
accumulation of protein aggregates and suppressed cytotoxic UPR [21], indicating that chemical
chaperones may be considered as a therapeutic strategy to target proteotoxic stress. Pathogenic
mutations in GTPBP3, another enzyme required for taurine modification, results in enzymatic activity
loss and decreased levels of taurine modification in mt-tRNAs of a two-year-old patient with a
mitochondrial disorder [8] (Figure 3; Table 1).
Disturbances of modifications at position 37 are particularly linked to metabolic dysfunction
and proteostasis imbalances. The mammalian methylthiotransferase CDKAL1, essential for the
generation of ms2t6A37 in cytoplasmic tRNALys(UUU), is required for the accurate translation of AAA
and AAG codons [89,100] (Figure 3; Table 1). Mice lacking CDKAL1 display a reduction in insulin
β-cells secretion and endoplasmic reticulum (ER) stress caused by misreading of lysine codons in
proinsulin. This indicates a link between deficient translation in the absence of CDKAL1 and increased
risk of type 2 diabetes [35,90]. In drosophila, lack of N6-threonylcarbamoyadenosine (t6A) at position
37 of tRNAs leads to the accumulation of aberrant proteins in the lumen of the ER and activation of the
UPR [101]. Recently, a t6A biosynthesis defect in humans due to a mutation in KAE1, a component of
the KEOPS complex that catalyzes the second biosynthetic step of t6A, was reported [34]. This mutation
is associated with renal tubulopathy and also with severe neurodegeneration [34]. Besides, mutant
mt-tRNAThr bearing the A15923G mutation isolated from MERFF-like patient fibroblast and myoblasts
displays low levels of t6A37, linking this hypomodification to pathological conditions [33].
TRIT1, a tRNA isopentenyl transferase that catalyzes i6A37 modification in mitochondrial and
cytosolic tRNAs is mutated in patients with mitochondrial disorders (Figure 3; Table 1). This mutation
causes i6A37 deficiency that is reversed by transfection of wildtype TRIT1 in patient′s fibroblasts [7].
3.3. tRNA-Modifying Enzymes that Catalyze tRNA Modifications outside the Anticodon Are Also Associated
with Disease
Mutations in the TRMT1 gene, which encodes an enzyme that demethylates guanosines
at position 26 of several tRNAs, have also been identified as the cause of certain forms of
autosomal-recessive intellectual disability [56] (Figure 3; Table 1). A recent study demonstrated that
TRMT1 catalyzes dimethylguanosine (m2,2G) modification in both mitochondrial and nucleus-encoded
tRNAs, as TRMT1-deficient cells lacked these modifications [80]. Expression of TRMT1 variants
found in intellectual disability patients in TRMT1 knockout cells is not sufficient to catalyze the
m2,2G modification at G26, whereas transfection of wildtype TRMT1 is able to recover tRNA G26
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modifications. Moreover, protein synthesis is negatively affected in TRMT1 knockout cells and redox
homeostasis is impaired, particularly in neural stem cells, indicating that this enzyme is important to
oxidative stress resistance and may regulate the translation of stress-response genes through m2,2G
modification [80].
A homozygous truncation mutation in PUS3 is also associated with intellectual disability [86]
(Figure 3; Table 1). Cells derived from patients bearing this mutation show decreased levels of
isomerization of uracil in positions 38 and 39 of tRNALeu, which require PUS3 activity, but no alterations
in the levels of other modifications [86].
TRMT10A is a tRNA-methyltransferase that catalyzes methylation of guanine-9 (m1G9). Several
studies have reported TRMT10A nonsense mutations in young-onset diabetes and microcephaly,
which is correlated with its enriched expression in the pancreas and brain [81–84] (Figure 3; Table 1).
Recently, tRNAGln and tRNAiMet were identified as TRMT10A targets. m1G is significantly reduced in
TRMT10A-deficient patient lymphoblasts and TRMT10A depletion induces β-cell oxidative stress and
generation of tRNA-derived fragments [85].
Decreased expression in the methyltransferase TRMT61B, which catalyzes m1A58 in three
mt-tRNA (mt-tRNALeu(UUR), mt-tRNASer(UCN), and mt-tRNALys) [102], has been observed in
Alzheimer′s disease [91] (Figure 3; Table 1). However, it is still unclear if the reduction of
TRMT61B-mediated methylation, or rather hypomethylation, of a specific TRMT61B substrate
is responsible for disease development. Nevertheless, lack of m1A58 modification is found in
tRNALys of patients carrying the mitochondrial DNA mutation m.8344A > G associated with MERRF
and is correlated with decreased protein synthesis rate. Overexpression of TRMT61B in MERRF
patient myoblasts is sufficient to restore m1A58 modification levels in tRNALys and increase the
synthesis of selected proteins [92], indicating that modifications of mt-tRNAs impact mitochondrial
gene expression.
4. tRNA Hypomodification and Generation of tRNA-Derived Fragments
tRNA-derived fragments are a heterogeneous class of molecules that derive from mature tRNAs
and play regulatory roles in a variety of cellular processes, namely, gene expression, translation
initiation and elongation, and stress granule assembly, among others. Many tRNA-derived fragments
have been implicated in cancer, neurodegenerative disorders, and infection, and emerging data
suggest that tRNA modifications play a critical role in the generation and accumulation of tRNA
fragments in human diseases [103]. In fact, tRNA hypomodification has been associated with the
accumulation of particular tRNA-derived fragments. For example, deletion of NSUN2 in mice and
humans induces the accumulation of 5´tRNA-derived fragments in brains as a result of m5C tRNA
hypomodification [26,104]. The accumulation of tRNA derived fragments triggers cellular stress
responses and, consequently, reduces protein translation rates, leading to decreased brain size and
affected synapse development in NSUN2 knockout mice embryos [26]. Moreover, inhibition of
angiogenin-mediated tRNA cleavage rescues the elevated stress levels of NSUN2(−/−) cells during
neurodevelopment in vivo [26], suggesting the protective role of NSUN2 modification in human
neurocognitive and intellectual disabilities. Taken together, these results show that m5C inhibit tRNA
cleavage and that NSUN2 is required for brain development.
Loss of TRMT10A in both lymphoblasts and iPSC-derived β-like cells leads to tRNA m1G9
hypomethylation, tRNAGln cleavage, and generation of 22 nucleotides and longer 5′tRNAGln
fragments [85]. These fragments are able to promote β-cell apoptosis, which is reversed by
transfection of a specific 5′tRNAGln antisense oligonucleotide [85], suggesting a role of tRNA-derived
fragments in the development of diabetes and β-cell dysfunction as a result of tRNA hypomodification.
Pseudouridylation of RNA catalyzed by PUS7 has been recently identified as a major activator of
a network of tRNA-derived fragments involved in translation regulation in embryonic human
stem cells (hESCs) [105]. Interestingly, PUS7 knockout in hESCs have increased de novo protein
synthesis, and tRNATyr(GUA) was identified as a PUS7 target. Moreover, loss of PUS7 leads to a
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decrease, rather than an increase, of particular 5′tRNA-derived fragments containing a 5′terminal
oligoguanine (TOG), derived from tRNAAla, tRNACys, and tRNAVal that are also PUS7 modified.
In fact, these pseudouridylated 5′ tRNA-derived fragments inhibit translation initiation, which is
required for translation control for accurate stem cell fate determination [105].
Taken together, these data indicate that lack of tRNA modifications has a direct impact on
the generation of tRNA-derived fragments implicated in pathological cellular processes. However,
additional studies are required to fully understand the correlation between tRNA modifications and
tRNA-derived fragments and how this is affected in different cell types and conditions.
5. Conclusions and Future Perspectives
Elucidation of the roles of tRNA modifications and tRNA-modifying enzymes in human
disease is starting to emerge. Several genetic mutations in tRNA-modifying enzymes have been
associated with pathological conditions, in particular, neurological and metabolic disorders, suggesting
that hypomodification of tRNAs contribute to the onset and/or development of human diseases
(Figure 3/Table 1). Recent advances in the role of the Elongator complex in the development of
neurological disorders has been crucial to highlight the importance of tRNA modifications in
proteostasis and human disease. It is also clear that although modifications at the wobble position are
fundamental for proteostasis, modifications in other tRNA sites seem to be equally relevant. It would be
interesting to perform large-scale screenings in mammalian cells to pinpoint which and how tRNA
modifications are involved in translation accuracy, efficiency, protein misfolding, and aggregation.
The emerging studies indicate that lack of particular modifications affects particular subsets of
tRNAs, affecting the translation of specific codons and protein subsets. The recent advances in ribosome
profiling, tRNA and mRNA sequencing, and mass spectrometry will undoubtedly contribute to
elucidate how tRNA modifications affect translation and proteostasis in disease contexts and,
equally important, which proteins are mainly affected by different tRNA processing defects.
The correlation between tRNA modifications and protein synthesis regulation suggests that
RNA modifications participate in the epigenetic control of gene expression at the translational level,
but further studies are necessary to clarify this issue. It is also important to keep in mind that some
tRNA-modifying enzymes have alternative noncanonical functions beyond tRNA modifications,
and that mutations in heterodimeric tRNA-modifying enzymes may directly affect other cellular
processes where these enzymes are involved, contributing to the phenotypes observed in particular
diseases. Additionally, the discovery of tRNA-derived fragments and their recent implications in many
diseases will provide valuable insights into human pathogenic mechanisms and will better clarify
the implications of tRNA modifications in the regulation of tRNA cleavage. It is still unclear whether
certain human pathologies associated with tRNA modifications and tRNA-modifying enzymes arise as
a direct consequence of altered translation of mRNAs or whether other uncharacterized mechanisms
are involved, but it is expected that this will be a main focus of research in this field.
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